Deborah T. Gold

Deborah T. Gold

Professor in Psychiatry and Behavioral Sciences

External address: 
1507 Busse Bldg, Durham, NC 27710
Internal office address: 
Box 3003 Med Ctr, Durham, NC 27710
(919) 660-7530


My research has centered on the psychosocial consequences of chronic illness for older adults. Although I have studied breast cancer, syncope, head and neck cancer, Parkinson's disease and Paget's disease of bone, my primary interest and focus has been on osteoporosis and its psychological and social impact on those who suffer from it.

In particular, my current research focuses on compliance and persistence with osteoporosis medications. One current study focuses on the impact of race/ethnicity on medication decision making. We are trying to determine the relative weight of cost, convenience, dosing interval, efficacy, and safety in making medication decisions and taking medication on a regular basis as prescribed by a health care provider. I am also on the Steering Committees of two major observational studies with different osteoporosis medications.

Finally, I have worked with voluntary health organizations to translate our research findings into positive real-world outcomes for people with chronic illness. I serve on the Board of Trustees of the National Osteoporosis Foundation and am Chair of its Education Committee. I have also chaired the International Symposium on Osteoporosis (ISO) for the last 8 years.

Education & Training

  • Ph.D., Northwestern University 1986

Silverman, S. L., et al. “Oral bisphosphonate compliance and persistence: a matter of choice?Osteoporos Int, vol. 22, no. 1, Jan. 2011, pp. 21–26. Pubmed, doi:10.1007/s00198-010-1274-6. Full Text

Gold, Deborah T., et al. “Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational Study.J Osteoporos, vol. 2011, 2011, p. 314970. Pubmed, doi:10.4061/2011/314970. Full Text

Gold, D. T., and S. L. Silverman. Adverse Health Outcomes in Men with Osteoporosis. Dec. 2010, pp. 395–401. Scopus, doi:10.1016/B978-0-12-374602-3.00032-8. Full Text

Silverman, Stuart, and Deborah T. Gold. “Compliance and persistence with osteoporosis medications: a critical review of the literature.Rev Endocr Metab Disord, vol. 11, no. 4, Dec. 2010, pp. 275–80. Pubmed, doi:10.1007/s11154-010-9138-0. Full Text

Abelson, A., et al. “Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.Osteoporos Int, vol. 21, no. 6, June 2010, pp. 1021–29. Pubmed, doi:10.1007/s00198-009-1046-3. Full Text

Kendler, D. L., et al. “Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.Osteoporos Int, vol. 21, no. 5, May 2010, pp. 837–46. Pubmed, doi:10.1007/s00198-009-1023-x. Full Text

Gold, D. T. Compliance and Persistence With Osteoporosis Medications. Dec. 2009, pp. 254–56. Scopus, doi:10.1002/9780470623992.ch54. Full Text

Gold, Deborah T., et al. “Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.Curr Med Res Opin, vol. 25, no. 8, Aug. 2009, pp. 1831–39. Pubmed, doi:10.1185/03007990903035604. Full Text

Whitson, Heather E., et al. “Correlation between symptoms and function in older adults with comorbidity.J Am Geriatr Soc, vol. 57, no. 4, Apr. 2009, pp. 676–82. Pubmed, doi:10.1111/j.1532-5415.2009.02178.x. Full Text

Gold, D. T., and S. Solimeo. The Conundrum of Compliance and Persistence with Oral Bisphosphonates for Postmenopausal Osteoporosis. Dec. 2008, pp. 1547–53. Scopus, doi:10.1016/B978-012370544-0.50066-5. Full Text